Prognostic Role of MicroRNA 222 in Patients with Glioma: A Meta-analysis

Background. Several studies have focused on the prognostic role of microRNA 222 in glioma. But different conclusions were drawn by these studies. We aimed to systematically evaluate the role of microRNA 222 in glioma by conducting a meta-analysis. Methods. A systematic literature search until January 2020 was conducted in Web of Science, EMBASE, Cochrane Library, PubMed, and China National Knowledge Infrastructure. The general characteristics and relevant data of nine articles were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to evaluate the prognostic role of microRNA 222 in glioma. The primary outcomes were overall survival (OS) and disease-free survival (DFS). Results. Nine articles (11 data sets) with 1564 patients were included. We systematically evaluated the role of microRNA 222 for OS and DFS in glioma patients (HR for OS=1.72; 95% CI, 1.31-2.26; p=0.001; HR for DFS=1.02; 95% CI, 0.86-1.22; p=0.032). Subgroup analyses were performed according to the sources of patients, the types of the samples, the stages of the tumors, the methods for detecting the microRNA 222, and the sample size. No significant publication bias was found. Conclusion. In conclusion, our study provided evidence that a high expression of microRNA 222 was related to worse overall survival in glioma patients. However, given the limited study number, more high-quality studies are warranted in the future.

Download Full-text

Prognostic Role of MicroRNA-126 for Survival in Malignant Tumors: A Systematic Review and Meta-Analysis

Disease Markers ◽

10.1155/2015/739469 ◽

2015 ◽

Vol 2015 ◽

pp. 1-11 ◽

Cited By ~ 6

Author(s):

Jie Bu ◽

Hui Li ◽

Xiao-yang Li ◽

Li-hong Liu ◽

Wei Sun ◽

...

Keyword(s):

Systematic Review ◽

Malignant Tumors ◽

Meta Analysis ◽

Cochrane Library ◽

Prognostic Role ◽

Patients With Cancer ◽

Hazard Ratios ◽

High Level ◽

The Cochrane Library

Background.Increasing studies found that miR-126 expression may be associated with the prognosis of cancers. Here, we performed a meta-analysis to assess the prognostic role of miR-126 in different cancers.Methods.Eligible studies were identified by searching in PubMed, Embase, the Cochrane Library, CNKI, and Wan Fang databases up to March 2015. Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated to investigate the correlation between miR-126 and survival of cancers.Results.Thirty studies including a total of 4497 participants were enrolled in this meta-analysis. The pooled results showed that high level of miR-126 was a predictor for favorable survival of carcinomas, with pooled HR of 0.77 (95% CI 0.64–0.93) for OS, 0.64 (95%CI 0.48–0.85) for DFS, and 0.70 (95% CI 0.50–0.98) for PFS/RFS/DSS. However, high level of circulating miR-126 predicted a significantly worse OS in patients with cancer (HR = 1.65, 95% CI 1.09–2.51).Conclusions.Our results indicated that miR-126 could act as a significant biomarker in the prognosis of various cancers.

Download Full-text

The Clinicopathologic and Prognostic Significance of c-Myc Expression in Hepatocellular Carcinoma: A Meta-Analysis

Frontiers in Bioinformatics ◽

10.3389/fbinf.2021.706835 ◽

2021 ◽

Vol 1 ◽

Author(s):

Zhao Min ◽

Zhang Xunlei ◽

Chen Haizhen ◽

Zhao Wenjing ◽

Yu Haiyan ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Publication Bias ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Cochrane Library ◽

Poor Overall Survival ◽

Hazard Ratios ◽

Incidence And Mortality

Background: The incidence and mortality rates of hepatocellular carcinoma (HCC) are increasing worldwide. Therefore, there is an urgent need to elucidate the molecular drivers of HCC for potential early diagnosis and individualized treatment. Whether c-Myc expression plays a role in the clinicopathology and prognosis of patients with HCC remains controversial. This meta-analysis aimed to survey the prognostic role of c-Myc in HCC.Methods: We searched PubMed, Cochrane Library, Embase, Web of Science, and Google Scholar databases for studies published through March 2020 that examined the association between c-Myc expression and clinicopathology or prognosis in HCC patients. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to investigate the prognostic significance of c-Myc expression. Odds ratios were calculated to evaluate the association between c-Myc expression and clinicopathologic features. We also tested for publication bias.Results: Our meta-analysis included nine studies with 981 patients with HCC published between 1999 and 2016. A meta-analysis of these studies demonstrated that high c-Myc expression indicated a poor overall survival (OS) (HR = 2.260, 95% CI: 1.660–3.080, and p < 0.001) and disease-free survival (DFS) (HR = 1.770, 95% CI: 1.430–2.450, and p < 0.001) in patients with HCC. However, high c-Myc expression was not associated with HBsAg, pathological type, TNM stage, or cirrhosis. We did not find any significant publication bias among the included studies, indicating that our estimates were robust and reliable.Conclusion: c-Myc overexpression could predict poor OS and DFS in HCC patients. c-Myc could be a useful prognostic biomarker and therapeutic target for HCC.

Download Full-text

The Prognostic Role of Micro-RNAs in Head and Neck Cancers: An Umbrella Review

Journal of Personalized Medicine ◽

10.3390/jpm11080821 ◽

2021 ◽

Vol 11 (8) ◽

pp. 821

Author(s):

Marco Mariani ◽

Carolina Castagna ◽

Stefania Boccia ◽

Roberta Pastorino

Keyword(s):

Head And Neck ◽

Systematic Reviews ◽

Meta Analysis ◽

Disease Free Survival ◽

Umbrella Review ◽

Prognostic Role ◽

Hazard Ratios ◽

Micro Rnas

We conducted an umbrella review which synthetizes the findings of systematic reviews available in the literature that investigate the prognostic role of miRNAs as potential biomarkers in the field of tertiary prevention of head and neck Cancer (HNC). We selected systematic reviews in English related to HNC, with meta-analysis of observational studies that reported quantitative prognostic measures, hazard ratios (HRs), overall survival (OS) or disease-free survival (DFS). The methodological quality of the included reviews was assessed by using the AMSTAR-2 tool. The most reported miRNAs were the following: miRNA2, Let7 family and miR17, etc. Four out of six reviews particularly emphasized the link between miRNA21 expression and HNC patients. Recently the cumulative effects of sets of miRNAs have been increasingly studied and might be a stronger predictor of survival than single miRNA.

Download Full-text

Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis

Cellular Physiology and Biochemistry ◽

10.1159/000487164 ◽

2018 ◽

Vol 45 (2) ◽

pp. 720-732 ◽

Cited By ~ 26

Author(s):

Xiao Zheng ◽

Xing Song ◽

Yingjie Shao ◽

Bin Xu ◽

Wenwei Hu ◽

...

Keyword(s):

Fixed Effects ◽

Meta Analysis ◽

Disease Free Survival ◽

Tumor Infiltrating Lymphocytes ◽

Cochrane Library ◽

Prognostic Role ◽

Cancer Specific Survival ◽

Esophagus Cancer ◽

Infiltrating Lymphocytes

Background/Aims: Several studies have verified the correlation between tumor-infiltrating lymphocytes (TILs) and survival of patients with esophagus cancer (EC). However, the prognostic role of TILs is still controversial. Therefore, we performed this meta-analysis. Methods: We searched PubMed, Embase and the Cochrane Library (last update by August 30, 2017) to identify studies assessing the effect of TILs on survival of patients with EC. Pooled hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS) and cancer specific survival (CSS) were estimated using fixed-effects models or random-effects models, which depends on the heterogeneity. Results: Data from 22 observational studies including 2909 patients were summarized. Pooled analysis indicated that generalized TILs were favorable prognostic markers for OS in patients with EC (pooled HR = 0.48; 95% CI = 0.38-0.61; P < 0.001). For TIL subsets, CD8+ TILs were associated with improved OS (pooled HR = 0.68; 95% CI = 0.58–0.84; P < 0.001) and DFS (pooled HR = 0.90; 95% CI = 0.85-0.95; P < 0.001); FoxP3+ TILs were associated with patients’ DFS (pooled HR = 0.88; 95% CI = 0.81-0.96; P = 0.003). High CD57+ TILs indicated a better OS in patients with EC (pooled HR = 0.50; 95% CI = 0.35-0.72; P < 0.001). In addition, the pooled results showed that other TIL subsets including CD3+, CD4+ and CD45RO+ TILs were not associated with patients’ survival (P > 0.05). Conclusions: For patients with EC, some TIL subsets could serve as prognostic biomarkers. The application of TILs in the immunotherapy of EC needs to be verified through a large amount of clinical research.

Download Full-text

Role of MALAT1 as a Prognostic Factor for Survival in Various Cancers: A Systematic Review of the Literature with Meta-Analysis

Disease Markers ◽

10.1155/2015/164635 ◽

2015 ◽

Vol 2015 ◽

pp. 1-9 ◽

Cited By ~ 23

Author(s):

Yao Wei ◽

Ben Niu

Keyword(s):

Prognostic Factor ◽

Noncoding Rna ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Tumor Type ◽

Prognostic Role ◽

Hazard Ratios ◽

Patient Prognosis

Objectives. The expression of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a highly abundant and ubiquitously expressed long noncoding RNA (lncRNA), influences clinical parameters and may have prognostic value in cancer. This meta-analysis evaluated the prognostic role of MALAT1 in various cancers.Materials and Methods. Systematic literature searches of PubMed and EMBASE databases were conducted for eligible studies of the prognostic role of MALAT1 in cancer. Overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were analyzed. Summary hazard ratios (HRs) and 95% confidence intervals (95% CIs) were assessed to evaluate the influence of MALAT1 expression on patient prognosis.Results. Nine studies with a total of 932 patients were included in the analysis. Elevated MALAT1 expression was significantly correlated with poor OS (HR 2.02; 95% CI: 1.62–2.52;P<0.001;I2=0%). Subgroup analysis indicated that tumor type, histology type, ethnicity, and measurement technique did not affect the prognostic value of MALAT1 for OS. The HR of elevated MALAT1 for DFS was 2.78 (95% CI: 1.87–4.15;P<0.001;I2=0%).Conclusions. Elevated MALAT1 expression is correlated with poor OS in various types of cancer, suggesting that this gene is a prognostic factor for different types of cancer.

Download Full-text

Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis

Frontiers in Medicine ◽

10.3389/fmed.2021.744518 ◽

2021 ◽

Vol 8 ◽

Author(s):

Yang An ◽

Shixue Xu ◽

Yiting Liu ◽

Xiangbo Xu ◽

Cyriac Abby Philips ◽

...

Keyword(s):

Overall Survival ◽

Liver Diseases ◽

Vascular Invasion ◽

Meta Analysis ◽

High Expression ◽

Cochrane Library ◽

Hazard Ratios ◽

Galectin 3 ◽

Mean Differences

Background: Galectins, a family of β-galactoside-binding proteins, are related to the development and progression of various human diseases such as cancer, heart failure, and chronic kidney disease. However, its role in liver diseases is unclear.Methods: The PubMed, Embase, and Cochrane Library databases were searched. Hazard ratios (HRs), odds ratios (ORs), and mean differences (MDs) with 95% CIs were pooled to evaluate the association of the galectins with the outcomes and risk of liver diseases by a random effects model.Results: Thirty three studies involving 43 cohorts and 4,168 patients with liver diseases were included. In the patients with hepatocellular carcinoma (HCC), high expression of galectin-1 and -3 in the tissues was significantly associated with worse overall survival (galectin-1: HR = 1.94, 95% CI = 1.61–2.34, p < 0.001; galectin-3: HR = 3.29, 95% CI = 1.62–6.68, p < 0.001) and positive vascular invasion (galectin-1: OR = 1.74, 95% CI = 1.18–2.58, p = 0.005; galectin-3: OR = 2.98, 95% CI = 1.58–5.60, p = 0.001); but, high expression of galectin-4 and −9 in the tissues was significantly associated with better overall survival (galectin-4: HR = 0.53, 95% CI = 0.36–0.79, p = 0.002; galectin-9: HR = 0.56, 95% CI = 0.44–0.71, p < 0.001) and negative vascular invasion (galectin-4: OR = 0.36, 95% CI = 0.19–0.72, p = 0.003; galectin-9: OR = 0.60, 95% CI = 0.37–0.97, p = 0.037). Serum galectin-3 level was significantly higher in HCC (MD = 3.06, 95% CI = 1.79–4.32, p < 0.001), liver failure (MD = 0.44, 95% CI = 0.23–0.66, p < 0.001), liver cirrhosis (MD = 1.83, 95% CI = 1.15–2.51, p < 0.001), and chronic active hepatitis B (MD = 18.95, 95% CI = 10.91–27.00, p < 0.001); serum galectin-9 level was significantly higher in HCC (MD = 3.74, 95% CI = 2.57–4.91, p < 0.001) and autoimmune hepatitis (MD = 8.80, 95% CI = 7.61–9.99, p < 0.001).Conclusion: High galectin-1 and -3 and low galectin-4 and -9 expression indicate worse outcomes of patients with HCC. Serum galectin-3 and -9 levels are positively associated with the risk of chronic liver diseases.

Download Full-text

Acupuncture for Cancer-Related Constipation: A Protocol for Systematic Review and Meta-Analysis

Acupuncture & Electro-Therapeutics Research ◽

10.3727/036012921x16237619666049 ◽

2021 ◽

Author(s):

Jing Xu ◽

Yupei Chen ◽

Yuzhuo Bai ◽

Jie Chen ◽

Li Zhang ◽

...

Keyword(s):

Meta Analysis ◽

Cochrane Review ◽

Clinical Effectiveness ◽

Cochrane Library ◽

China National Knowledge Infrastructure ◽

Knowledge Infrastructure ◽

Classification Management ◽

The Cochrane Library ◽

Review Manager

Objective: By evaluating the clinical effectiveness and safety, we can better understand the role of acupuncture for cancer-related constipation treatment and provide guidance for clinicians. Methods: We searched some academic databases (PubMed, MEDLINE, EMBASE, the Cochrane Library, Elsevier SD journal, Springer journal, Chinese Biomedicine, China National Knowledge Infrastructure, Chinese Wanfang Data, Chinese VIP Data, etc.). All documents were loaded into Endnote X8 for classification management. After extracting the data, two reviewers assessed the risk bias of each original study using the tool Cochrane manual v.5.1.0. Cochrane Review Manager 5.3 will be used to conduct this meta-analysis. Results: With the data, we can better evaluate the clinical effectiveness and safety of acupuncture for cancer-related constipation treatment. Conclusion: This study aimed to identify the best acupuncture therapy for cancer-related constipation to guide clinicians and patients.

Download Full-text

Prognostic Value of MicroRNA-497 in Various Cancers: A Systematic Review and Meta-Analysis

Disease Markers ◽

10.1155/2019/2491291 ◽

2019 ◽

Vol 2019 ◽

pp. 1-9 ◽

Cited By ~ 2

Author(s):

Zhiqiang Liu ◽

Shanshan Wu ◽

Lei Wang ◽

Shuling Kang ◽

Bixing Zhao ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Biomarker ◽

Data Extraction ◽

Meta Analysis ◽

Disease Free Survival ◽

Cancer Prognosis ◽

Cancer Type ◽

Free Survival ◽

Knowledge Infrastructure ◽

Hazard Ratios

Background. Some studies showed that microRNA-497 (miR-497) might act as a prognostic biomarker of cancer. However, the conclusion was not consistent. The aim of this study was to investigate the prognostic role of miR-497 in various carcinomas. Methods. We systematically searched the databases of PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang Data to identify relevant studies. Two independent reviewers performed the data extraction and assessed the study quality. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for overall survival (OS) and disease-free survival/relapse-free survival (DFS/RFS) were used to assess the associations between miR-497 expression and cancer prognosis. Results. A total of 15 studies involving 1760 participants fulfilled the inclusion criteria. The lower level of miR-497 expression was significantly associated with shorter overall survival (HR=2.19, 95% CI: 1.84-2.60). No significant association was found between miR-497 expression and DFS/RFS in various carcinomas (HR=1.17, 95% CI: 0.53-2.57). Subgroup analyses by ethnicity and cancer type showed the consistent results. Conclusion. Our studies suggested that miR-497 might be a prognostic biomarker in cancers. However, further multicenter prospective clinical researches are needed to confirm the association between miR-497 expression and cancer prognosis.

Download Full-text

Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20180618 ◽

2019 ◽

Vol 39 (1) ◽

Cited By ~ 1

Author(s):

Xichen Wang ◽

Kang Chen ◽

Haipeng Liu ◽

Zeping Huang ◽

Xiao Chen ◽

...

Keyword(s):

Solid Tumors ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Pooled Analysis ◽

Prognostic Role ◽

Free Survival ◽

Hazard Ratios ◽

Human Solid Tumors

AbstractA consensus about the prognostic role of NIMA-related kinase 2 (NEK2) expression in various solid tumors has not been made yet. Thus, this meta-analysis aimed to systematically assess the prognostic role of NEK2 expression in patients with solid tumors. The eligible studies were identified through searching PubMed, Web of Science, and EMBASE. The hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were used to evaluate the link between NEK2 overexpression and overall survival (OS) and disease-free survival/recurrence-free survival (DFS/RFS) of patients with solid tumors. A total of 17 studies with 4897 patients were included in this meta-analysis. Among these studies, all of them explored the association between NEK2 expression and OS of patients with solid tumors. Our pooled analysis indicated that NEK2 overexpression was significantly related to adverse OS (HR = 1.66; 95% CI: 1.38–2.00; P = 0.001). Additionally, there were six studies with 854 patients that investigated the association between NEK2 expression and DFS/RFS. Our pooled result indicated that there was a substantial relationship between NEK2 overexpression and poorer DFS/RFS (HR = 2.00; 95% CI: 1.61–2.48; P = 0.003). In conclusion, our meta-analysis indicated that NEK2 may be a useful predictor of prognosis and an effective therapeutic target in solid tumors. Nevertheless, more high-quality studies are warranted to further support our conclusions because of several limitations in our meta-analysis.

Download Full-text

Comparison of the overall survival of proximal and distal gastric cancer after gastrectomy: a systematic review and meta-analysis

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02126-4 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Jiaming Xue ◽

Huiliang Yang ◽

Shanshan Huang ◽

Tingting Zhou ◽

Xiangwen Zhang ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Meta Analysis ◽

Cochrane Library ◽

Inclusion Criteria ◽

China National Knowledge Infrastructure ◽

Future Studies ◽

Western Countries ◽

Knowledge Infrastructure ◽

Distal Gastric Cancer

Abstract Background The aim of this study was to investigate the overall survival (OS) between proximal gastric cancer (PG) and distal gastric cancer (DG) patients after gastrectomy. Methods Articles on the prognostic study of PG and DG patients after gastrectomy were collected from the PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases from the date of establishment until December 2020. The data were statistically analyzed by Stata software (version 11.0, StataCorp). Results A total of 10 articles met the inclusion criteria. Meta-analysis showed that the 1-, 3- and 5-year OS rates of PG patients were significantly lower than those of DG patients (RR = 0.898, 95% CI: 0.825 to 0.977, P = 0.013; RR = 0.802, 95% CI: 0.708 to 0.909, P = 0.001; RR = 0.736, 95% CI: 0.642 to 0.844, P = 0.000). After subgroup analysis according to different countries, the combined RR values of were as follows: 1-year OS: eastern countries: RR = 0.966, 95% CI: 0.944 to 0.988, P = 0.003, western countries: RR = 0.687, 95% CI: 0.622 to 0.759, P = 0.000; 3-year OS: eastern countries: RR = 0.846, 95% CI: 0.771 to 0.929, P = 0.000, western countries: RR = 0.742, 95% CI: 0.399 to 1.382, P = 0.348; and 5-year OS: eastern countries: RR = 0.798, 95% CI: 0.716 to 0.889, P = 0.000, western countries: RR = 0.646, 95% CI: 0.414 to 1.008, P = 0.054. Conclusion In terms of 1-, 3-, and 5-year OS, PG patients had lower rates than DG patients and the eastern countries/western countries subgroup, but there were no significant differences in 3- and 5-year OS for the western countries. These results merit further clinical validation in future studies. (Registration ID: UMIN000040393; Date of registration: 2020/05/13)

Download Full-text